Showing 1 - 6 of 6 Bincy Abraham

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Mayyadah Al-Sabbagh

Phone: 346.238.0307

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease. BI 706321 is a medicine being dev ... Read more >

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequa ... Read more >

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequat ... Read more >

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice. ... Read more >

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >